Jennifer Arnold, MD

Jennifer Arnold, MD

Neurologist
Neurology
Accepting new patients
Call for an appointment
217-545-8000
or
Request appointment

    About me

    Gender

    Female

    Education & training

    Positions
    Assistant Professor, Neurology
    Medical School
    MD, University of Illinois
    Doctorate Degree
    Ph.D. Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign
    Undergraduate Degree
    BS Biology, Southeast Missouri State University
    Residency
    Neurology, University of Michigan
    Fellowship
    Neurodegenerative Diseases, University of Michigan

    Specialties

    Treatments & procedures

    Patients in waiting room

    Appointments

    SIU Medicine strongly encourages all patients to verify coverage, benefits and which providers are considered in-network with their health plan. SIU Medicine has more than 300 health care providers ready to serve you and your family. SIU Medicine accepts a wide variety of governmental and non-governmental health plans to serve our community. 

    Clinical locations

    Locations

    SIU Neurology Clinic

    751 N. Rutledge St. Springfield, IL 62702 Suite 3100
    Get Directions
    Mon - Fri: 8:00 am-4:30 pm
    217-545-8000

    Hospital privileges

    • HSHS St. John's Hospital, Springfield, IL
    • Memorial Health, Springfield IL

    Clinical trials

    Trial
    Neurology

    A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease (TargetTau-1)

    Active recruiting

    The purpose of this study is to assess the effect of BMS-986446 vs placebo on delay of cognitive memory and functional decline in participants (age 50-80) with early Alzheimer's Disease.

    Contact: Sara Boarman 217-545-6829
    Trial
    Neurology

    Lilly: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

    Active not recruiting

    I5T-MC-AACI:  The purpose of this study is to assess the effect of donanemab versus placebo on clinical regression in participants with early symptomatic Alzheimer's disease with presence of low-medium tau pathology.

    Contact: Sara Boarman 217-545-6829
    Trial
    Neurology

    Lilly: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

    Active not recruiting

    I5T-MC-AACI:  The purpose of this study is to assess the effect of donanemab versus placebo on clinical regression in participants with early symptomatic Alzheimer's disease with presence of low-medium tau pathology.

    Contact: Sara Boarman 217-545-6829